Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0249. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0249 SCHEMBL29378542 | 1.00 | HRH3 (1.00) | HRH3KCNH2ADRA1A | |
| SCHEMBL4475999 | 0.99 | HRH3 (0.98) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150097 | 0.92 | HRH3 (0.85) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150010 | 0.91 | HRH3 (0.84) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150087 | 0.90 | HRH3 (0.81) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150041 | 0.90 | HRH3 (0.81) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150048 | 0.89 | HRH3 (0.79) | HRH3KCNH2ADRA1A | |
| SCHEMBL4470886 | 0.88 | HRH3 (0.78) | HRH3KCNH2ADRA1A | |
| SCHEMBL12150173 | 0.88 | HRH3 (0.78) | HRH3KCNH2ADRA1A | |
| SCHEMBL4476679 | 0.88 | HRH3 (1.00) | HRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | claimed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | claimed |
| EP-2424528-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| CN-1918128-B | fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD | 2011-01-26 | — | — | CN | claimed |
| WO-2010129242-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | claimed |
| US-7790731-B2 | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-09-07 | — | — | US | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090131664-A1 | Method for Producing 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2009-05-21 | — | — | US | claimed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | claimed |
| US-20080139589-A1 | Crystal of 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1903040-A1 | METHOD FOR PRODUCING 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-03-26 | — | — | EP | claimed |
| EP-1852423-A1 | CRYSTAL OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | claimed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | claimed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| US-20240148745-A1 | COMPOUNDS FOR USE IN PROGRESSIVE MULTIPLE SCLEROSIS | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2024-05-09 | — | — | US | disclosed |
| EP-3924343-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2006085692-A1 | CRYSTAL OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD (JP) | 2006-08-17 | — | — | WO | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 805/4885ADRA1A 446/4885 |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 805/4885ADRA1A 446/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | HRH3 24/4885KCNH2 1554/4885ADRA1A 88/4885 |
| US-20080139589-A1 | Crystal of 4(3H)-Quinazolinone Derivative | HRH3, HRH1, HRH4 | HRH3 1/4885KCNH2 224/4885ADRA1A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.